Sponsors (16)
The bill extends and strengthens oversight, transparency, and data requirements for ALS and related programs—potentially improving patient access and aligning R&D—at the cost of increased reporting burdens, slower processing risks, legal ambiguity in one amendment, and additional federal spending.
Patients with ALS and related neurodegenerative conditions, plus researchers and hospitals, keep access to the Act's programs and authorities for five more years (2027–2031), preserving existing expedited pathways and program continuity.
People with ALS could gain more research-informed access to investigational drugs because applicants must describe how expanded-access data will support ALS research, strengthening the link between expanded access and evidence generation.
Patients, developers, and stakeholders get clearer, more transparent FDA action plans (documenting prior actions, planned steps, and implementation barriers), improving accountability and helping stakeholders understand regulatory priorities.
Taxpayers face continued and potentially increased federal spending obligations (authorization extension and possible resource requests to address identified barriers), which could raise budgetary costs over the extended period.
Expanded reporting, evaluation, and renewal-assessment duties increase administrative burden on HHS and FDA (and may require more staff or funding), potentially slowing grant processing and regulatory actions.
Grantees and drug sponsors must share trial safety and expanded-access data promptly, increasing reporting workload and administrative costs for developers, institutions, and hospitals.
Based on analysis of 6 sections of legislative text.
Reauthorizes the ALS program for 2027–2031 and tightens grant, reporting, and FDA action-plan rules for ALS and rare neurodegenerative disease therapies.
Official title: Amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.
Introduced April 30, 2026 by Lisa Murkowski · Last progress April 30, 2026
Extends and updates the federal program that supports development of drugs, devices, and related regulatory science for amyotrophic lateral sclerosis (ALS) by moving the five-year authorization window forward to cover 2027–2031 and revising grant, reporting, and FDA action-plan requirements. The bill clarifies application and review requirements for ALS-focused grants, requires additional reporting and reviewer duties, expands FDA action plans to explicitly include rare neurodegenerative diseases and adds implementation detail, and adjusts the statutory reporting schedule to add an HHS report in addition to a GAO report.